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There are intense commercial pressures in industry to develop
drugs for large unselected populations, although this remains a
risky and expensive strategy. Several examples now exist where
targeted treatments are utilised in molecularly defined cancer
patient populations. The EGFR tyrosine kinase inhibitor (TKI)
gefitinib is a case in point, failing to show a clear benefit in non-
small-cell lung cancer (NSCLC) patients when given with first-line
chemotherapy. Gefitinib has nevertheless re-emerged as an
important therapeutic following the confirmation that mutations
in the TK domain of EGFR confer sensitivity to it (Mok et al, 2009),
with evidence that this population is enriched within Asian, female
and never-smoker patients with adenocarcinoma (Lynch et al,
2004; Paez et al, 2004). More recently, two large-phase III trials,
investigating the addition of the fully human monoclonal antibody
(mAb) to the insulin-like growth factor 1 receptor (IGF-1R)
figitumumab (CP-751,871, Pfizer) to carboplatin/paclitaxel (AD-
VIGO 1016) and to the EGFR TKI erlotinib (ADVIGO 1018), in
advanced NSCLC patients have been suspended after planned
interim analyses indicated futility (Jassem et al, 2010). These data
raise several important questions: Was there sufficient evidence to
support these phase III trials? Could we have learnt more from
early-phase data to identify the patients who are most likely to
benefit? Is IGF-1R a key target in NSCLC? How should we design
our trials to identify predictive biomarkers that decrease the risk
of such late and costly failures?
Gualberto and colleagues now publish valuable data in this
edition of The British Journal of Cancer (Gualberto et al, 2010b)
evaluating putative predictive circulating biomarkers of sensitivity
to figitumumab. Their study highlights the complexities of
predictive biomarker clinical qualification. They conclude that,
independent of tumour characteristics, pre-treatment free IGF-1
(fIGF-1) concentration is a predictive biomarker of clinical benefit
from figitumumab at 20mg kg1 but not at 10mg kg1 in NSCLC.
Their results are consistent with observations that low IGF-1 levels
are associated with prolonged survival in NSCLC (Han et al, 2006).
Nevertheless, their finding that higher baseline fIGF-1 is present in
females and patients with adenocarcinoma is at odds with reported
data indicating that patients with squamous cell carcinoma derive
more benefit from figitumumab and calls into question whether
this is simply a prognostic biomarker (Karp et al, 2009a).
Importantly, however, in this manuscript under discussion, pre-
treatment fIGF-1 was not predictive of PFS in patients receiving
chemotherapy alone, suggesting that this may not be simply a
prognostic biomarker. Recent reports profiling molecular deter-
minants of sensitivity to figitumumab also identified increased
IGF-1R expression within squamous cell tumours, which were
more likely to respond, but could not definitively establish whether
this was a prognostic or predictive factor (Gualberto et al, 2010a).
Overall, analysis of these data is complicated by the small
sample size and the biological heterogeneity of patients on trial,
which are common issues in such clinical research. Their use of
one-sided tests limits the statistical power and calls into question
whether this study is adequately powered. Moreover, the addition
of chemotherapy renders the determination of biomarkers that
are truly figitumumab-specific more complex. Other factors that
cannot be underestimated are measures of the analytical validity of
the assay. Overall, evaluation of the reproducibility and variability
of the assay by using two baseline readings should be recom-
mended for such studies. Indeed, concerns remain that current
assay methodologies to measure IGF-1 bioactivity are controversial
and imperfect (Frystyk, 2007).
Despite these criticisms, these attempts to detect circulating
predictive biomarkers are to be commended. We are convinced that
circulating predictive biomarkers are critically important in cancer
research; these are repeatable, less invasive and more easily
implemented in large randomized trials. Nonetheless, the relation-
ship between circulating biomarkers and tumour characteristics
must be analysed to evaluate whether these reflect tumour biology.
Moreover, pre-treatment biomarkers provide a ‘snapshot’ suggesting
which patients may benefit from treatment, but repeated analyses are
required to establish a picture of adaptive changes through acquired
resistance mechanisms. Indeed, earlier phase I trials evaluating
figitumumab reported that treatment was associated with increased
circulating IGF-1 levels and decreased soluble IGF-1R from baseline
(Lacy et al, 2008; Molife et al, 2010). This supports repeated analyses
of such biomarkers, which is best done through circulating
biomarkers. Importantly, the feedback increase in IGF-1 post
treatment with figitumumab may explain why the higher dose of
20mgkg1 is more active than the 10mgkg1 dose.
Figitumumab phase I trial data suggested that bioactive IGF-1
levels may influence treatment sensitivity following the observa-
tion of responses in patients treated with figitumumab at doses
above 10mg kg1 who had a high baseline free fIGF-1 to
IGF-binding protein-3 (IGF-BP3) ratio (Karp et al, 2009b). In a
phase II, randomised NSCLC trial of first-line paclitaxel/carbopla-
tin (PC) alone or in combination with figitumumab (PCF), the
combination resulted in an impressive overall response rate (ORR)
of 54% (Karp et al, 2009a). Intriguingly, there was an apparent
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dose response to figitumumab in both ORR and 12-week PFS in
patients with adenocarcinoma and squamous cell carcinoma
histology, with the greatest benefit seen with the higher antibody
dose of 20mg kg1 (78% ORR and 89% 12-week PFS). Moreover,
anti-tumour activity was observed in two patients with squamous
histology receiving figitumumab monotherapy after PC discontinua-
tion for progression. Despite this, no patient stratification or
population enrichment based on histological subtype, IGF-1R tumour
expression or circulating fIGF1 levels was pursued in Phase III trials
(Jassem et al, 2010).
Several questions remain; deregulation of the IGF signalling axis
in NSCLC is supported by findings that increased IGF-1 and low
levels of its binding protein IGF-BP3 are associated with an
increased risk of lung cancer (Yu et al, 1999; Han et al, 2006).
Furthermore, IGF-1R is frequently over-expressed in NSCLC,
mediating signalling that results in tumour growth and drug
resistance (Morgillo et al, 2007). However, IGF-1-overexpressing
transgenic mice with functionally upregulated IGF-1R are predis-
posed towards increased formation of adenomata but not
malignant tumours, whereas preclinical work indicates that IGF-
II may instead be the critically important autocrine/paracrine
ligand in NSCLC by also signalling via the insulin receptor (IR)
(Quinn et al, 1996; Ulanet et al, 2010). It remains to be seen
whether treatments targeting both IGF-1R and IR, or both IGF-1
and IGF-II, in NSCLC will yield different results (Olmos et al,
2010a). Nonetheless, we have observed impressive anti-tumour
activity of figitumumab in metastatic Ewing’s sarcoma as a single
agent, with some patients experiencing durable responses up to 3
years, suggesting that targeting IGF-1R alone deserves further
evaluation (Olmos et al, 2010b).
Finally, several different strategies can be pursued to gain most
information from early-phase studies. These include phase I trial
expansions, phase II Bayesian adaptive designs where all-comers
are initially treated, but patients are then enriched for ‘responding
phenotypes’ as in the Biomarker-Integrated Approaches of
Targeted Therapy for Lung Cancer Elimination (BATTLE) clinical
trial programme, and randomised phase II trials with either
a priori selection of patients with or without the presence of the
biomarker or, as in this case, a retrospective analysis of putative
biomarkers against outcome from treatment. Overall, however, we
urgently need to develop smarter trial designs that can accelerate
the clinical qualification of putative predictive biomarkers in
concert with targeted drug trials to expedite the successful delivery
of less costly drug approval and patient benefit. Although the
initial and NSCLC trials of figitumumab have been negative, the
evaluation of drugs targeting the IGF pathway should continue. We
should not throw out the baby with the bathwater.
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